Johnson & Johnson (JNJ) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

With its stock down 12% over the past three months, it is easy to disregard Johnson & Johnson (NYSE:JNJ). However, stock ...

Shares of Johnson & Johnson JNJ slid 0.27% to $146.24 Thursday, on what proved to be an all-around rough trading session for ...

Johnson & Johnson (JNJ) stock saw a decline, ending the day at $149.23 which represents a decrease of $-0.37 or -0.25% from the prior close of $149.6. The stock opened at $149.93 and touched a low of ...

and Johnson & Johnson. Rishabh Mishra Bristol-Myers Squibb Files Lawsuit Against US Agency For Overreach In 340B Drug Pricing Program Bristol Myers Squibb sues HRSA, claiming its rejection of a ...

Key Insights Given the large stake in the stock by institutions, Johnson & Johnson's stock price might be vulnerable ...

This was the stock's second consecutive day of losses.

Wolfe Research has recently initiated Johnson & Johnson (JNJ) stock to Outperform rating, as announced on November 15, 2024, according to Finviz. Earlier, on July 23, 2024, Daiwa Securities had ...

Given its better prospects, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pharmaceutical pick over Johnson & Johnson stock (NYSE: JNJ). BMY stock trades at 8.3x its ...